20KK0359, 22K06117, and 22KK0099 to YS, no
10.1517/17460441.2013.741580 76 PattersonJ
Scott Kahan, an obesity medicine specialist in Washington, D.C., said its very important that patients continue to get enough calories, even though the medication will make them feel less hungry
GLP-1 binds to receptors (GLP-1R) in the hindbrain, hypothalamus, lateral septum and cortex, engaging circuits that inhibit food intake (extensively reviewed in previous work 8 )
Conclusion Tirzepatide marks a notable advancement in the management of type 2 diabetes and obesity, demonstrating its dual action on GLP-1 and GIP receptors to enhance insulin secretion and facilitate weight loss